Skip to content

Radiomics-based Non-invasive Classifier Research for HCC-related Liver Transplantation

Radiomics-based Non-invasive Classifier Research for HCC-related Liver Transplantation

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03981848
Enrollment
200
Registered
2019-06-11
Start date
2019-07-31
Completion date
2021-12-31
Last updated
2019-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular Carcinoma, Liver Transplantation, Magnetic Resonance Imaging

Brief summary

The purpose of this study is to establish a non-invasive radiomics method to filter high recurrent-risk liver transplantation recipient population

Detailed description

Hepatocellular carcinoma is one of the most common malignant tumors in the world with high incidence and mortality. Liver transplantation is the most effective treatment for HCC and is in high demand in China. However, recurrence of HCC among liver transplantation recipients is still a great challenge and threat to the survival of recipients. So it is of great significance to establish a non-invasive way to filter high liver transplantation recipient population before transplantation. Based on large scales of pre-treatment MR images, the investigator's study aims to establish a non-invasive radiomics method to filter high recurrent-risk liver transplantation recipient population. This study will contribute to the precise selection of HCC-related liver transplantation recipients.

Interventions

High risk factor model of tumor relapse after liver transplantation

Sponsors

Fudan University
CollaboratorOTHER
Zhejiang University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* All patients had postoperative pathological diagnosis of HCC * All patients had underwent contrast-enhanced MRI scan within 2 weeks before liver transplantation

Exclusion criteria

* patients whose pathological diagnosis is not HCC * patients whose CT images were affected by strong imaging artifacts, i.e. artifacts obscuring more than 10% of whole volume of interest * patients whose clinical data or CT images were missing

Design outcomes

Primary

MeasureTime frame
tumor recurrent statustwo years

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026